Merck initiates long-term study on Sotatercept for Pulmonary Arterial Hypertension
Merck is conducting a long-term follow-up study to assess the safety and tolerability of Sotatercept in patients with PAH.
Therapeutic Area
Therapeutic area intelligence for Targeted Therapy with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.